New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
Lupus study shows promising results using umbilical cord mesenchymal stem cells
NANJING, Jiangsu, China, June 7 /PRNewswire-Asia/ -- A new study
shows that umbilical cord mesenchymal stem cell transplant
(UC-MSCT) may improve symptoms and biochemical values in patients
with severe refractory systemic lupus erythematosus (SLE).
In research published online (ahead of print) May 6, 2010 in
Arthritis & Rheumatism, lead author and Director of
Rheumatology and Immunology at Nanjing University Medical School's
renowned Drum Tower Hospital Dr. Lingyun Sun and colleagues report
on 16 patients with severe SLE that did not respond to standard
treatments. All 16 patients received stem cell transplants. Ten
patients completed at least 6 months of follow-up and 2 patients
were followed for more than 2 years. There was no treatment-related
mortality or other adverse event during or after UC-MSCT, according
to the article.
In comments to Reuters on the report, Dr. Sun said, "The disease
activity among patients was significantly improved during the first
3 months of follow-up." After nearly two years, "most patients show
clinical remission with no adverse events detected to date or
treatment-related mortality."
Dr. Sun added, "We have been working with multiple centers in
China for our further studies with more patients being recruited
and longer periods for follow-up, which will be compared to the
standard treatment to determine the long-term efficacy and safety
of this novel approach to treat refractory lupus."
The umbilical cord-derived mesenchymal stem cells used in the
study were processed by Beike Biotech's scientists (http://www.beikebiotech.com/ ) at the company's
new state-of-the-art Jiangsu Stem Cell Regenerative Medicine
Facility in Taizhou, China. The facility was recently awarded
ISO9001 certification for its stem cell processing.
One of the world's leading stem cell researchers, Dr. Sun has
done extensive work in stem cell therapies yielding numerous papers
on his clinical trial results in the academic journals Lupus, Stem
Cells, and Arthritis & Rheumatism.
Beike Biotechnology Chairman Dr. Sean Hu commented, "This study
marks an important research milestone in the field of stem cell
interventions and an important follow-up to Dr. Sun's previous
studies on lupus and stem cells. We are pleased to see the promise
UC-MSCT holds for SLE patients as indicated by the data and look
forward to the publication of follow-up studies."
View the article's abstract at http://www3.interscience.wiley.com/journal/123421837/abstract
About Beike Biotechnology Company Limited:
Beike Biotechnology (http://www.beikebiotech.com/) is Asia's leading
biotechnology company focusing on adult stem cell therapies.
Beike's scientists have been focused on the development and
commercialization of adult stem cell therapies since 1999. The
company currently produces a full line of stem cell products from
umbilical cord, cord blood, and bone marrow stem cells. Beike's
stem cell therapies are administered by physicians at leading
hospitals throughout China.
Beike's unique processing technologies prepare the cells for use
in treating a variety of serious medical conditions including
ataxia, brain injury, cerebral palsy, diabetic foot disease, lower
limb ischemia, multiple sclerosis, muscular dystrophy, spinal cord
injury and optic nerve pathologies.
For more information, please contact: Shenzhen Beike Biotechnology Company, Ltd. T. Gutmann Shenzhen Hi-Tech Industrial Park Tel: +86-755-8630-9200 Email: info@beikebiotech.com Web: http://www.beikebiotech.com/
Source: Beike Biotechnology Company Limited
CONTACT: T. Gutmann, Shenzhen Beike Biotechnology Company, Ltd.
at
+86-755-8630-9200 or info@beikebiotech.com
Web site: http://www.beikebiotech.com/
Posted: June 2010
